It is the central hypothesis of this grant that the protein kinase, glycogen synthase kinase-3b (GSK-3b) is a negative regulator of hypertrophic growth of the heart. Over the past several years we have presented evidence to support that hypothesis. However, virtually all of the work in this area has relied upon over-expression of GSK-3b, and this can cause spurious results. This reliance on over-expression strategies has been necessitated by the embryonic lethality caused by deletion of the GSK-3b gene. Herein, we propose to definitively determine the role of this kinase and its isoform, GSK-3a, in the hypertrophic response using genetic loss of function approaches. This is now possible due to the recent creation by our long-time collaborator, Dr. James Woodgett, of mice in which either GSK-3b or GSK-3a can be conditionally deleted, selectively in the heart. Thus we propose to determine the role of GSK-3b in the hypertrophic response to three clinically relevant models: 1) banding of the aorta, mimicking aortic valve disease, 2) myocardial infarction, and 3) the """"""""two-kidney one clip"""""""" model of systemic hypertension. We will also determine what role, if any, GSK-3a plays in hypertrophic responses- an area that is, to our knowledge, totally unexplored. Finally, we will make use of a mouse we have recently created that conditionally expresses an inhibitory mutant of lymphocyte enhancer factor-1 (Lef-1), a transcription factor that is an obligate partner of b-catenin, a key downstream target of GSK-3b that we have recently found regulates the hypertrophic response. We will employ this mouse to attempt to identify novel targets of b-catenin that are expressed following pressure overload and that, therefore, might play a role in the genetic re-programming that is necessary for hypertrophy. We believe the studies outlined herein could identify novel targets, inhibition of which could retard or reverse the process of hypertrophy, a major risk factor for heart failure, stroke, and myocardial infarction. ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL061688-12
Application #
7439163
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Adhikari, Bishow B
Project Start
1999-09-20
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
12
Fiscal Year
2008
Total Cost
$387,500
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Zhou, Jibin; Ahmad, Firdos; Parikh, Shan et al. (2016) Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circ Res 118:1208-22
Zhou, Jibin; Ahmad, Firdos; Lal, Hind et al. (2016) Response by Zhou et al to Letter Regarding Article, ""Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy"". Circ Res 119:e29-e30
Lal, Hind; Ahmad, Firdos; Woodgett, James et al. (2015) The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 116:138-49
Ahmad, Firdos; Lal, Hind; Zhou, Jibin et al. (2014) Cardiomyocyte-specific deletion of Gsk3? mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. J Am Coll Cardiol 64:696-706
Lal, Hind; Ahmad, Firdos; Parikh, Shan et al. (2014) Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circ J 78:1514-9
Lal, Hind; Ahmad, Firdos; Zhou, Jibin et al. (2014) Cardiac fibroblast glycogen synthase kinase-3? regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 130:419-30
Zhou, Jibin; Freeman, Theresa A; Ahmad, Firdos et al. (2013) GSK-3? is a central regulator of age-related pathologies in mice. J Clin Invest 123:1821-32
Ky, Bonnie; Vejpongsa, Pimprapa; Yeh, Edward T H et al. (2013) Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 113:754-64
Lal, Hind; Kolaja, Kyle L; Force, Thomas (2013) Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol 61:267-74
Vagnozzi, Ronald J; Gatto Jr, Gregory J; Kallander, Lara S et al. (2013) Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med 5:207ra141

Showing the most recent 10 out of 43 publications